Benefits and costs of methadone treatment: results from a lifetime simulation model
Author
Abstract
Suggested Citation
DOI: 10.1002/hec.999
Download full text from publisher
References listed on IDEAS
- Zaric, G.S. & Barnett, P.G. & Brandeau, M.L., 2000. "HIV transmission and the cost-effectiveness of methadone maintenance," American Journal of Public Health, American Public Health Association, vol. 90(7), pages 1100-1111.
- Ellis, Bruce & Bernichon, Tiffiny & Yu, Ping & Roberts, Tracy & Herrell, James M., 2004. "Effect of social support on substance abuse relapse in a residential treatment setting for women," Evaluation and Program Planning, Elsevier, vol. 27(2), pages 213-221, May.
- Weinstein, M.C. & Coxson, P.G. & Williams, L.W. & Pass, T.M. & Stason, W.B. & Goldman, L., 1987. "Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model," American Journal of Public Health, American Public Health Association, vol. 77(11), pages 1417-1426.
- zarkin, Gary A. & French, Michael T. & Anderson, Donald W. & Bradley, Cathy J., 1994. "A conceptual framework for the economic evaluation of substance abuse interventions," Evaluation and Program Planning, Elsevier, vol. 17(4), pages 409-418.
- French, Michael T. & McCollister, Kathryn E. & Sacks, Stanley & McKendrick, Karen & De Leon, George, 2002. "Benefit-cost analysis of a modified therapeutic community for mentally ill chemical abusers," Evaluation and Program Planning, Elsevier, vol. 25(2), pages 137-148, May.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
- Kevin N. Griffith & Lawrence M. Scheier, 2013. "Did We Get Our Money’s Worth? Bridging Economic and Behavioral Measures of Program Success in Adolescent Drug Prevention," IJERPH, MDPI, vol. 10(11), pages 1-28, November.
- Christine Godfrey, 2006. "Evidence-Based Illicit Drug Policy: The Potential Contribution of Economic Evaluation Techniques," De Economist, Springer, vol. 154(4), pages 563-580, December.
- Gary A. Zarkin & Alexander J. Cowell & Katherine A. Hicks & Michael J. Mills & Steven Belenko & Laura J. Dunlap & Kimberly A. Houser & Vince Keyes, 2012. "Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 633-652, June.
- Alison Ritter & Nagesh Shukla & Marian Shanahan & Phuong Van Hoang & Vu Lam Cao & Pascal Perez & Michael Farrell, 2016. "Building a Microsimulation Model of Heroin Use Careers in Australia," International Journal of Microsimulation, International Microsimulation Association, vol. 9(3), pages 140-176.
- Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
- Emanuel Krebs & Jeong E. Min & Elizabeth Evans & Libo Li & Lei Liu & David Huang & Darren Urada & Thomas Kerr & Yih-Ing Hser & Bohdan Nosyk, 2017. "Estimating State Transitions for Opioid Use Disorders," Medical Decision Making, , vol. 37(5), pages 483-497, July.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Michael T. French & M. Christopher Roebuck & Michael L. Dennis & Susan H. Godley & Howard A. Liddle & Frank M. Tims, 2003. "Outpatient Marijuana Treatment for Adolescents," Evaluation Review, , vol. 27(4), pages 421-459, August.
- Mark Roberts & Louise B. Russell & A. David Paltiel & Michael Chambers & Phil McEwan & Murray Krahn, 2012. "Conceptualizing a Model," Medical Decision Making, , vol. 32(5), pages 678-689, September.
- Rasstrigin, M. & Kitaev, A. & Pleshackova, E., 2023. "Forecasting spending on orphan diseases to maintain the long-run financial sustainability of healthcare system," Journal of the New Economic Association, New Economic Association, vol. 59(2), pages 120-141.
- William S. Weintraub & Samuel S. Gidding, 2016. "PCSK9 Inhibitors: A Technology Worth Paying For?," PharmacoEconomics, Springer, vol. 34(3), pages 217-220, March.
- Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette, 2006. "Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada," PharmacoEconomics, Springer, vol. 24(8), pages 815-830, August.
- Gregory S. Zaric & Margaret L. Brandeau & Paul G. Barnett, 2000. "Methadone Maintenance and HIV Prevention: A Cost-Effectiveness Analysis," Management Science, INFORMS, vol. 46(8), pages 1013-1031, August.
- Sabina S Alistar & Douglas K Owens & Margaret L Brandeau, 2014. "Effectiveness and Cost Effectiveness of Oral Pre-Exposure Prophylaxis in a Portfolio of Prevention Programs for Injection Drug Users in Mixed HIV Epidemics," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-11, January.
- Stephanie Earnshaw & Katherine Hicks & Anke Richter & Amanda Honeycutt, 2007. "A linear programming model for allocating HIV prevention funds with state agencies: a pilot study," Health Care Management Science, Springer, vol. 10(3), pages 239-252, September.
- Michael F. Drummond;Adrian Towse, 1998. "From Efficacy to Cost-Effectiveness," Briefing 000438, Office of Health Economics.
- Yizhe Xu & Tom H. Greene & Adam P. Bress & Brian C. Sauer & Brandon K. Bellows & Yue Zhang & William S. Weintraub & Andrew E. Moran & Jincheng Shen, 2022. "Estimating the optimal individualized treatment rule from a cost‐effectiveness perspective," Biometrics, The International Biometric Society, vol. 78(1), pages 337-351, March.
- Sabina Alistar & Elisa Long & Margaret Brandeau & Eduard Beck, 2014. "HIV epidemic control—a model for optimal allocation of prevention and treatment resources," Health Care Management Science, Springer, vol. 17(2), pages 162-181, June.
- Mihic, Marko M. & Todorovic, Marija Lj. & Obradovic, Vladimir Lj., 2014. "Economic analysis of social services for the elderly in Serbia: Two sides of the same coin," Evaluation and Program Planning, Elsevier, vol. 45(C), pages 9-21.
- Logan, TK & Hoyt, William H. & McCollister, Kathryn E. & French, Michael T. & Leukefeld, Carl & Minton, Lisa, 2004. "Economic evaluation of drug court: methodology, results, and policy implications," Evaluation and Program Planning, Elsevier, vol. 27(4), pages 381-396, November.
- Emanuel Krebs & Jeong E. Min & Elizabeth Evans & Libo Li & Lei Liu & David Huang & Darren Urada & Thomas Kerr & Yih-Ing Hser & Bohdan Nosyk, 2017. "Estimating State Transitions for Opioid Use Disorders," Medical Decision Making, , vol. 37(5), pages 483-497, July.
- Zhang, Sheldon X. & Roberts, Robert E.L. & McCollister, Kathryn E., 2009. "An economic analysis of the in-prison therapeutic community model on prison management costs," Journal of Criminal Justice, Elsevier, vol. 37(4), pages 388-395, July.
- Elisa F. Long & Naveen K. Vaidya & Margaret L. Brandeau, 2008. "Controlling Co-Epidemics: Analysis of HIV and Tuberculosis Infection Dynamics," Operations Research, INFORMS, vol. 56(6), pages 1366-1381, December.
- Zarkin, Gary A. & Dunlap, Laura J. & Homsi, Ghada, 2004. "The substance abuse services cost analysis program (SASCAP): a new method for estimating drug treatment services costs," Evaluation and Program Planning, Elsevier, vol. 27(1), pages 35-43, February.
- Meltzer, David, 1997. "Accounting for future costs in medical cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 16(1), pages 33-64, February.
- Bob J. H. van Kempen & Bart S. Ferket & Albert Hofman & Sandra Spronk & Ewout Steyerberg & M. G. Myriam Hunink, 2012. "Do Different Methods of Modeling Statin Treatment Effectiveness Influence the Optimal Decision?," Medical Decision Making, , vol. 32(3), pages 507-516, May.
- Michael T. French & Helena J. Salomé & Antoinette Krupski & James R. Mckay & Dennis M. Donovan & A. Thomas Mclellan & Jack Durell, 2000. "Benefit-Cost Analysis of Residential and Outpatient Addiction Treatment in the State of Washington," Evaluation Review, , vol. 24(6), pages 609-634, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:14:y:2005:i:11:p:1133-1150. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/5749 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.